Singapore based Good Pharma Dermatology has appointed marketing communications agency, Onyx Health to manage the commercialisation and UK launch of their fast growing consumer itch-relief product, Suu BalmTM.
Onyx Health are now developing and implementing a brand and market entry strategy for Suu BalmTM in the UK, which will be a launched in 600 Lloyds Pharmacy in September 2017.
Suu BalmTM is currently available in 6 countries across Asia and most recently launched in Ireland, May 2016 before coming to the UK. Suu BalmTM is a fast-acting itch-relief moisturising cream, specifically developed by a leading research and clinical focussed dermatologist for people suffering from itchy, dry or sensitive skin.
Jason Humphries one of the two co-founders of Good Pharma Dermatology had previously run the GSK dermatology portfolio in the UK. He saw the opportunity for a novel, well differentiated consumer dermatology brand here. Along with his co-founder Dr. John O’Shea, they developed the strategy to use Ireland as a test bed and to gain UK / Ireland retail chain interest to springboard to the larger UK market.
Dr John O’Shea, says, “We are extremely excited to be working with Onyx Health, who came highly recommended to us. For us, they have the right values, project management, communications and key account management experience to help introduce Suu BalmTM to UK consumers. They have been vital in introducing Suu BalmTM with high-street retailers and I cannot wait to see our product on UK shelves in the coming weeks.
“When we were introduced to Good Pharma Dermatology, we recognised straight away the gap in the market Suu BalmTM would fill”, says Onyx Health Director, Karen Winterhalter. “People suffering from eczema, psoriasis, and others skin conditions that cause severe itch, have very limited treatment options to choose from. The opportunity to bring Suu BalmTM to UK consumers was extremely appealing to us as we love taking a product and building a brand to achieve high volume sales.”
Onyx Health work with a broad range of healthcare clients, including life sciences, pharmaceutical, medical device, diagnostic and consumer health companies wanting to enter global and UK markets.